ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2026)

ARS Pharmaceuticals has reported Interest Coverage Ratio for 7 years, with the latest figure at 1.69 in Q1 2026.

• Quarterly Interest Coverage Ratio rose 99.95% year-over-year to 1.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.69 (up 99.77% YoY) and the FY2025 annual result came in at 2.3, down 5224.51% from the prior year.
• Interest Coverage Ratio climbed to 1.69 in Q1 2026 per SPRY's latest filing, from 18.98 in the prior quarter.
• Over five years, Interest Coverage Ratio peaked at 0.0 in Q1 2023 and troughed at 3379.73 in Q1 2025.
• A 5-year average of 238.52 and a median of 0.83 in 2022 frame the typical range for Interest Coverage Ratio.
• The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio surged 99.97% in 2023, then plunged 1986412.08% in 2025.
• Over 5 years, Interest Coverage Ratio stood at 154.43 in 2022, then jumped by 100.0% to 0.0 in 2023, then slumped by 22032750.92% to 256.51 in 2024, then surged by 92.6% to 18.98 in 2025, then soared by 91.09% to 1.69 in 2026.
• According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.69, 18.98, and 0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.